Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
about
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronScreening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator.Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse.Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.Drug-induced long QT syndromeDiscovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.Contrasting time- and rate-based approaches for the assessment of drug-induced QT changes.Antimicrobial-associated QT interval prolongation: pointes of interest.Editors' review of 2006 and the BJCP prize.Principles of safety pharmacology.hERG gating microdomains defined by S6 mutagenesis and molecular modeling.Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.On the relationship among QT interval, atrial fibrillation, and torsade de pointes.Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodRisk of arrhythmia induced by psychotropic medications: a proposal for clinical management.Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?Antihistamines modulate the integrin signaling pathway in h9c2 rat cardiomyocytes: Possible association with cardiotoxicity.Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine?Assessing risk of a prolonged QT interval-a survey of emergency physicians.Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs.Automated versus manual measurement of the QT interval and corrected QT interval.Analysis of an ECG record database reveals QT interval prolongation potential of famotidine in a large Korean population.
P2860
Q26746211-9F6A58D2-32A3-474D-989B-BFA4ABD963AFQ27343160-D0ABE13E-325D-4366-A681-B1DBA521AC21Q31129877-13E44B0C-97EE-4888-8D9B-5D745BB04C03Q33661027-C45EC1A2-1CF5-4574-82F1-404F40EE0442Q33745061-97443C9E-7DE7-41DB-8B84-45A64A3A0543Q33790423-01419451-9CEE-4935-8230-4A2EC5DA4A9BQ33911355-1E35456B-9E81-4459-8F18-61EAF40CE9F7Q34358104-D7736A08-C857-4496-A04D-A10CB7326E68Q34613962-1DEC118D-7BA9-49EF-A267-220A29274643Q34656447-3582E1C4-81F6-4B15-B1FE-8273E6A1676FQ36655034-A53B0C9F-EAEA-45D0-90A9-6314C36680FFQ36710219-D71AAC3F-0CD2-4E5A-B903-174C62E3B1C0Q36801850-929DAE05-1CA5-430B-9F82-49F98471F318Q36946670-E1B250CF-D444-4059-A193-CDCD271EA66FQ36987981-3A12F512-4307-4C33-80F6-9A59B48D2EF1Q37008418-9DBB0BDD-DA24-436B-B22D-D73202B4E819Q37156289-3342A665-2BAA-48C6-BB36-2FAC96EFF300Q38197159-CC8C5AA5-C4FB-4BE1-8DB2-99B5ABD7EC3EQ38819976-22C576D3-B71E-45A4-9AAD-C9D045BDC792Q38937713-BB74A384-B309-4AD0-A259-304161D08210Q40026484-B9751787-DDD6-4EB9-B5D0-B00441A8617FQ42361494-0F58DA7B-56CF-4C10-9CCF-314ECB943BEEQ42409996-7F64A29F-FD4D-4E22-87CE-E96121635B2FQ42530795-DE471B1B-644F-44F5-9AD3-2F3E5629C3E6Q43258119-4B518C55-13D5-4B9E-A3AE-ECD60233ABBAQ46087923-AC2D1607-8E86-4344-93B9-3618C296297FQ47146166-3765F73F-015B-4FDC-A325-065690C57CCCQ49143489-82F9BE3A-AD4E-45AB-9565-0E7E7BE2B374Q53061115-D5A68AC7-82FF-4878-B9B4-A1A75C49B2FFQ53155133-11314275-2D8C-4345-A3F1-A113EF54040FQ53258367-3040B5AD-BEC0-4CA1-8ABD-D5453B5A996F
P2860
Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@ast
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@en
type
label
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@ast
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@en
prefLabel
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@ast
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@en
P1433
P1476
Drugs, QTc interval prolongati ...... lestone with challenges ahead.
@en
P2093
Rashmi R Shah
P304
P356
10.2165/00002018-200528110-00003
P577
2005-01-01T00:00:00Z
P6179
1026069519